Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) is positioning itself at the intersection of artificial intelligence and precision medicine, targeting the growing cardiovascular disease market with its blood-based tests that aim to improve early detection and diagnosis. The company’s proprietary AI-driven Multi-Omics Engine analyzes genetic and epigenetic biomarkers to assess heart attack risk and identify coronary heart disease, including nonobstructive forms that conventional diagnostic methods may miss.
The cardiovascular disease market is projected to grow from $393 billion in annual healthcare costs in 2020 to $1.4 trillion by 2050, according to the press release. Cardio Diagnostics addresses this with its Epi+Gen CHD and PrecisionCHD tests, which leverage epigenetics, genetics, and artificial intelligence. The company has strengthened its commercialization efforts through securing finalized CMS reimbursement rates and dedicated CPT laboratory codes, expanding U.S. provider partnerships and launching its first international expansion in India.
With a proprietary AI-driven platform that has achieved reimbursement milestones and growing provider adoption, Cardio Diagnostics occupies a position that is both scientifically grounded and commercially actionable in the diagnostics landscape. The company’s tests are designed to detect what traditional tools may miss, offering a more personalized approach to cardiovascular disease prevention, detection, and management.
Cardio Diagnostics was formed to further develop and commercialize clinical tests by leveraging its AI-driven Integrated Genetic-Epigenetic Engine, aiming to become a leading medical technology company for improving prevention, detection, and treatment of cardiovascular disease. For more information, visit https://cdio.ai/.
The latest news and updates relating to CDIO are available in the company’s newsroom at https://nnw.fm/CDIO.
This development underscores the growing role of AI in precision medicine, particularly for conditions that are costly and widespread like cardiovascular disease. As the market expands, innovations that improve early detection could have significant implications for healthcare costs and patient outcomes.
